Goldman Sachs: The next generation IO-ADC is expected to lead Fiberhome Hanlin's global pipeline layout. It is first rated as "buy" with a target price of 100.70 Hong Kong dollars.

According to the Securities Times APP, Goldman Sachs released a research report stating that Fosun Pharma (02696.HK)'s next-generation IO-ADC (combination therapy of tumor immunotherapy and antibody-conjugated drugs) will lead its global pipeline layout. The stock was given a first-time "buy" rating, with a target price of 100.70 Hong Kong dollars in 12 months. This target price represents a 52.3% upside from the closing price of 66.10 Hong Kong dollars on Thursday.